Alterations of CSF Cystatin C Levels and Their Correlations with CSF Aβ40 and Aβ42 Levels in Patients with Alzheimer's Disease, Dementia with Lewy Bodies and the Atrophic Form of General Paresis

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Zhong, Xiao Mei ^a   Hou, Le ^a   Luo, Xin Ni ^a   Shi, Hai Shan ^a   Hu, Guo Yan ^a   He, Hong Bo ^a   Chen, Xin Ru ^a   Zheng, Dong ^a   Zhang, Yue Feng ^a   Tan, Yan ^a   Liu, Xue Jun ^a   Mu, Nan ^a   Chen, Jian Ping ^a   Ning, Yu Ping ^a  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; CYSTATIN C;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HUMAN; LEWY BODY; MAJOR CLINICAL STUDY; MALE; PARESIS; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN METABOLISM;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; CREATINE; CYSTATIN C; GLOMERULAR FILTRATION RATE; HUMANS; IMMUNOHISTOCHEMISTRY; LEWY BODY DISEASE; NEUROSYPHILIS; PEPTIDE FRAGMENTS; STATISTICS, NONPARAMETRIC;

EID: 84873806591     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0055328     Document Type: Article

References (43)

1. Mussap M, Plebani M, (2004) Biochemistry and clinical role of human cystatin C. Crit Rev Clin Lab Sci. 41: 467-550.
2. Levy E, Jaskolski M, Grubb A, (2006) The role of cystatin C in cerebral amyloid angiopathy and stroke: cell biology and animal models. Brain Pathol 16: 60-70.
3. Gauthier S, Kaur G, Mi W, Tizon B, Levy E, (2011) Protective mechanisms by cystatin C in neurodegenerative diseases. Front Biosci (Schol Ed) 3: 541-554.
4. Kaur G, Levy E, (2012) Cystatin C in Alzheimer's disease. Front Mol Neurosci 5: 79.
5. Sastre M, Calero M, Pawlik M, Mathews PM, Kumar A, et al. (2004) Binding of cystatin C to Alzheimer's amyloid beta inhibits in vitro amyloid fibril formation. Neurobiol Aging 25: 1033-1043.
6. Mi W, Pawlik M, Sastre M, Jung SS, Radvinsky DS, et al. (2007) Cystatin C inhibits amyloid-beta deposition in Alzheimer's disease mouse models. Nat Genet 39: 1440-1442.
7. Kaur G, Mohan P, Pawlik M, DeRosa S, Fajiculay J, et al. (2010) Cystatin C rescues degenerating neurons in a cystatin B-knockout mouse model of progressive myoclonus epilepsy. Am J Pathol 177: 2256-2267.
8. Pirttila TJ, Lukasiuk K, Hakansson K, Grubb A, Abrahamson M, et al. (2005) Cystatin C modulates neurodegeneration and neurogenesis following status epilepticus in mouse. Neurobiol Dis 20: 241-253.
9. Tizon B, Sahoo S, Yu H, Gauthier S, Kumar AR, et al. (2010) Induction of autophagy by cystatin C: a mechanism that protects murine primary cortical neurons and neuronal cell lines. PLoS One 5: e9819.
10. Levy E, Sastre M, Kumar A, Gallo G, Piccardo P, et al. (2001) Codeposition of cystatin C with amyloid-beta protein in the brain of Alzheimer disease patients. J Neuropathol Exp Neurol 60: 94-104.
11. Maruyama K, Ikeda S, Ishihara T, Allsop D, Yanagisawa N, (1990) Immunohistochemical characterization of cerebrovascular amyloid in 46 autopsied cases using antibodies to beta protein and cystatin C. Stroke. 21: 397-403.
12. Haan J, Maat-Schieman ML, van Duinen SG, Jensson O, Thorsteinsson L, et al. (1994) Co-localization of beta/A4 and cystatin C in cortical blood vessels in Dutch, but not in Icelandic hereditary cerebral hemorrhage with amyloidosis. Acta Neurol Scand 89: 367-371.
13. Itoh Y, Yamada M, Hayakawa M, Otomo E, Miyatake T, (1993) Cerebral amyloid angiopathy: a significant cause of cerebellar as well as lobar cerebral hemorrhage in the elderly. J Neurol Sci 116: 135-141.
14. Querfurth HW, LaFerla FM, (2010) Alzheimer's disease. N Engl J Med 362: 329-344.
15. Fujishiro H, Iseki E, Higashi S, Kasanuki K, Murayama N, et al. (2010) Distribution of cerebral amyloid deposition and its relevance to clinical phenotype in Lewy body dementia. Neurosci Lett 486: 19-23.
16. Edison P, Rowe CC, Rinne JO, Ng S, Ahmed I, et al. (2008) Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C] PIB positron emission tomography. J Neurol Neurosurg Psychiatry 79: 1331-1338.
17. Miklossy J, (2008) Biology and neuropathology of dementia in syphilis and Lyme disease. Handb Clin Neurol 89: 825-844.
18. Wang J, Guo Q, Zhou P, Zhang J, Zhao Q, et al. (2011) Cognitive impairment in mild general paresis of the insane: AD-like pattern. Dement Geriatr Cogn Disord 31: 284-290.
19. Esiri MM, (2007) The interplay between inflammation and neurodegeneration in CNS disease. J Neuroimmunol 184: 4-16.
20. Miklossy J, Rosemberg S, McGeer PL (2006) Beta amyloid deposition in the atrophic form of general paresis. In: Iqbal K, Winblad B, Avila J, editors. Alzheimer's Disease: New Advances Proceedings of the 10th International Congress on Alzheimer's Disease (ICAD): Medimond, International Proceedings. 429-443.
21. Levy E, Carman MD, Fernandez-Madrid IJ, Power MD, Lieberburg I, et al. (1990) Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage, Dutch type. Science 248: 1124-1126.
22. Crawford FC, Freeman MJ, Schinka JA, Abdullah LI, Gold M, et al. (2000) A polymorphism in the cystatin C gene is a novel risk factor for late-onset Alzheimer's disease. Neurology 55: 763-768.
23. Kaeser SA, Herzig MC, Coomaraswamy J, Kilger E, Selenica ML, et al. (2007) Cystatin C modulates cerebral beta-amyloidosis. Nat Genet 39: 1437-1439.
24. Chuo LJ, Sheu WH, Pai MC, Kuo YM, (2007) Genotype and plasma concentration of cystatin C in patients with late-onset Alzheimer disease. Dement Geriatr Cogn Disord 23: 251-257.
25. Sundelof J, Arnlov J, Ingelsson E, Sundstrom J, Basu S, et al. (2008) Serum cystatin C and the risk of Alzheimer disease in elderly men. Neurology 71: 1072-1079.
26. Hansson SF, Andreasson U, Wall M, Skoog I, Andreasen N, et al. (2009) Reduced levels of amyloid-beta-binding proteins in cerebrospinal fluid from Alzheimer's disease patients. J Alzheimers Dis 16: 389-397.
27. Simonsen AH, McGuire J, Podust VN, Hagnelius NO, Nilsson TK, et al. (2007) A novel panel of cerebrospinal fluid biomarkers for the differential diagnosis of Alzheimer's disease versus normal aging and frontotemporal dementia. Dement Geriatr Cogn Disord 24: 434-440.
28. Mares J, Kanovsky P, Herzig R, Stejskal D, Vavrouskova J, et al. (2009) The assessment of beta amyloid, tau protein and cystatin C in the cerebrospinal fluid: laboratory markers of neurodegenerative diseases. Neurol Sci 30: 1-7.
29. Sundelof J, Sundstrom J, Hansson O, Eriksdotter-Jonhagen M, Giedraitis V, et al. (2010) Cystatin C levels are positively correlated with both Abeta42 and tau levels in cerebrospinal fluid in persons with Alzheimer's disease, mild cognitive impairment, and healthy controls. J Alzheimers Dis 21: 471-478.
30. Craig-Schapiro R, Kuhn M, Xiong C, Pickering EH, Liu J, et al. (2011) Multiplexed immunoassay panel identifies novel CSF biomarkers for Alzheimer's disease diagnosis and prognosis. PLoS One 6: e18850.
31. Perrin RJ, Craig-Schapiro R, Malone JP, Shah AR, Gilmore P, et al. (2011) Identification and validation of novel cerebrospinal fluid biomarkers for staging early Alzheimer's disease. PLoS One 6: e16032.
32. McKhann G, Drachman D, Folstein M, Katzman R, Price D, et al. (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34: 939-944.
33. McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, et al. (2005) Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65: 1863-1872.
34. Ghanem KG, (2010) REVIEW: Neurosyphilis: A historical perspective and review. CNS Neurosci Ther 16: e157-168.
35. Maetzler W, Schmid B, Synofzik M, Schulte C, Riester K, et al. (2010) The CST3 BB genotype and low cystatin C cerebrospinal fluid levels are associated with dementia in Lewy body disease. J Alzheimers Dis 19: 937-942.
36. Blennow K, Zetterberg H, Fagan AM (2012) Fluid biomarkers in Alzheimer disease. Cold Spring Harb Perspect Med 2.
37. Yamamoto-Watanabe Y, Watanabe M, Jackson M, Akimoto H, Sugimoto K, et al. (2010) Quantification of cystatin C in cerebrospinal fluid from various neurological disorders and correlation with G73A polymorphism in CST3. Brain Res 1361: 140-145.
38. Benussi L, Ghidoni R, Steinhoff T, Alberici A, Villa A, et al. (2003) Alzheimer disease-associated cystatin C variant undergoes impaired secretion. Neurobiol Dis 13: 15-21.
39. Nagai A, Kobayashi S, Shimode K, Imaoka K, Umegae N, et al. (1998) No mutations in cystatin C gene in cerebral amyloid angiopathy with cystatin C deposition. Mol Chem Neuropathol 33: 63-78.
40. Selenica ML, Wang X, Ostergaard-Pedersen L, Westlind-Danielsson A, Grubb A, (2007) Cystatin C reduces the in vitro formation of soluble Abeta1-42 oligomers and protofibrils. Scand J Clin Lab Invest 67: 179-190.
41. Ghidoni R, Benussi L, Glionna M, Desenzani S, Albertini V, et al. (2010) Plasma cystatin C and risk of developing Alzheimer's disease in subjects with mild cognitive impairment. J Alzheimers Dis 22: 985-991.
42. McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, et al. (1999) Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol 46: 860-866.
43. Nitsch RM, Rebeck GW, Deng M, Richardson UI, Tennis M, et al. (1995) Cerebrospinal fluid levels of amyloid beta-protein in Alzheimer's disease: inverse correlation with severity of dementia and effect of apolipoprotein E genotype. Ann Neurol 37: 512-518.